Participant flow

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer · Source last updated 2013-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47.

   id

   FG000

   title

   Arm A (Cisplatin and Radiotherapy)

2. description

   Patients receive cisplatin and radiotherapy as in Arm A. Patients also receive erlotinib hydrochloride PO QD on days -7 to 47.

   id

   FG001

   title

   Arm B (Cisplatin, Radiotherapy, Erlotinib)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         105

      2. group Id

         FG001

         num Subjects

         99

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         96

      2. group Id

         FG001

         num Subjects

         95

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Patients were randomized between December 2006 and October 2011.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice